# A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

> **NCT06525935** · PHASE2 · COMPLETED · sponsor: **Carmot Therapeutics, Inc.** · enrollment: 469 (actual)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Placebo
- **DRUG:** Enicepatide

## Key facts

- **NCT ID:** NCT06525935
- **Lead sponsor:** Carmot Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-16
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 469 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525935, "A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06525935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*